Results 71 to 80 of about 44,809 (280)

Rapid resolution of hypertriglyceridemia-induced pancreatitis via plasmapheresis: A unique case report

SAGE Open Medical Case Reports, 2022
Hypertriglyceridemia is a well-established cause of acute pancreatitis. Initial treatment for hypertriglyceridemia-induced pancreatitis has consisted of supportive measures; however, triglyceride levels can remain high, causing prolonged organ failure ...
Victoria Wang, Anna Jinnah, James R Pellegrini, Brandon Pelletier   +3 more
doaj   +1 more source

Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Evinacumab, an angiopoietin‐like 3 inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). Herein, we report pharmacokinetic and efficacy analyses of evinacumab in < 5‐year‐old patients with HoFH.
Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Katy C. Norman, Richard T. George, Xue‐Qiao Zhao, Robert Pordy, Daniel Garcia, Wendy S. Putnam, Geetha Raghuveer, Brian W. McCrindle, Elena Fornari, Ivo Baric, Shubha Srinivasan, Melissa Diamond, Eliot A. Brinton, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch   +18 more
wiley   +1 more source

Nipocalimab Dose Selection in Generalized Myasthenia Gravis

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
Model‐Informed Nipocalimab Dose Selection for Generalized Myasthenia Gravis. ABSTRACT Nipocalimab is a fully human immunoglobulin G (IgG)1 monoclonal antibody (mAb) designed to selectively block the IgG binding site of neonatal fragment crystallizable receptor (FcRn) to inhibit IgG recycling and decrease circulating IgG, including pathogenic IgG ...
Belén Valenzuela, Martine Neyens, Yaowei Zhu, Sindhu Ramchandren, Anne‐Gaëlle Dosne, Jocelyn H. Leu, Ruben Faelens, Leona E. Ling, Juan‐José Pérez‐Ruixo   +8 more
wiley   +1 more source

Never say never

Journal of Hospital Medicine, EarlyView.
Gurpreet Dhaliwal, Jagmeet Dhingra, Tom Fraser, Leal Herlitz, James Pile   +4 more
wiley   +1 more source

Plasmapheresis in Acute Hypertriglyceridemia‐Induced Pancreatitis—The PHIP‐JuGa‐Study

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background and Aims The incidence of acute pancreatitis is increasing in the Western world. About 10% of cases are caused by hypertriglyceridemia. Plasmapheresis was shown to reduce serum triglyceride (TG) levels, and current apheresis guidelines recommend its use in severe acute hypertriglyceridemia‐induced pancreatitis (HIP).
Jonas J. Staudacher, Elisabeth Blüthner, Katharina Murillo, Manja Boldt, Karim Hamesch, Leah Kruse, Sabrina Sulzer, Christoph Ammer‐Herrmenau, Yvonne Huber, Julia Weinmann‐Menke, Charlotte Kramer, Jakob Garbe, Rene Wilke, Marcus M. Mücke, Myriam W. Heilani, Elisabeth Orgler‐Gasche, Marlies Vornhülz, Georg Beyer, Lara Wiesehahn, Annekatrin Schwanstecher, Marcus Hollenbach, Hendrik Luxenburger, Dominik Bettinger, Sophie Schlosser‐Hupf, for the JuGa study group   +24 more
wiley   +1 more source

Effective Preoperative Plasmapheresis Treatment of Severe Hyperthyroidism in a Patient with Giant Toxic Nodular Goiter and Methimazole-Induced Agranulocytosis

Medicina, 2020
Agranulocytosis is a rare but very serious complication of thyrostatic therapy. In severe hyperthyroidism, the removal of circulating thyroid hormones by plasmapheresis may be an effective therapeutic option.
Katarzyna Barwinek, Danuta Gąsior-Perczak, Sławomir Trepka, Artur Szczodry, Janusz Kopczyński, Zdzisława Sitarz-Żelazna, Aldona Kowalska   +6 more
doaj   +1 more source

Influence of patient factors on target plasma volume treated attainment rate during double filtration plasmapheresis in patients with hypertriglyceridemic acute pancreatitis

Therapeutic Apheresis and Dialysis, EarlyView.
Abstract Introduction This study aims to investigate patient factors affecting the rate of plasma volume target attained in hypertriglyceridemic pancreatitis (HTG‐AP) patients undergoing double filtration plasmapheresis (DFPP). Methods A retrospective analysis of 82 HTG‐AP‐interpreted patients from January 2019 to April 2024 compared target plasma ...
Hui Zhang, Chenqiang Zhu, Yunlong Wu
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Liver transplantation across ABO blood groups [PDF]

, 1986
Six hundred seventy-one first, second, and third orthotopic liver allografts in 520 patients were reviewed to determine the effect of donor-recipient mismatches or incompatibility for the ABO blood group on graft survival. A significant advantage for ABO
Esquivel, CO, Gordon, RD, Iwatsuki, S, Starzl, TE, Todo, S, Tzakis, A   +5 more
core  

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K., Anderson, J., Andrews, S., Arrindell, D., Ballesteros, J., Bingham, C. O., Boyer, J., Brogdon, C., Chen, D., Chonzi, D., Cotarla, I., Cunha, R., Dadu, R., Davies, M., Dawson, M., Diab, A., Dicker, Adam, Eifler, L., Ernstoff, M. S., Ferguson, A., Ferlini, C., Frankel, S., Go, W., Gochett, C., Goldberg, J., Goncalves, P., Goswami, T., Gregory, N., Gulley, J. L., Hamad, L., Hayreh, V., Helie, N., Holmes, W., Hsu, J. Y., Ibrahim, R., Kaufman, H. L., Kim, S., Lacouture, M. E., Lambotte, O., Larocca, C., LeBoeuf, N. R., Lehman, K., Lenihan, D., Ley-Acosta, S., Luke, J., McClure, J., Michelon, E., Nakamura, M., Onofrei, C., Patel, K., Piperdi, B., Puzanov, I., Rasheed, Z., Reshef, D., Riemer, J., Robert, C., Sarkeshik, M., Saylors, A., Schreiber, J., Shafer-Weaver, K., Shannon, V., Sharfman, W., Sharma, R., Sharon, E., Sherry, R., Silk, A. W., Simonson, C., Skondra, D., Suarez-Almazor, M. E., Thomas, C., Thompson, J. A., Trehu, E., Tresnan, D., Turner, M., Wang, Y., Wariabharaj, D., Waxman, I., Wiley, K., Wood, L., Zhang, L., Zheng, P.   +80 more
core   +2 more sources